Literature DB >> 32258786

Blood pressure and phosphate level in diabetic and non-diabetic kidney disease: Results of the cross-sectional "Low Clearance Consultation" study.

Margarida Mendes1, Luis Resende2, Alves Teixeira2, João Correia3, Gil Silva2.   

Abstract

HIGHLIGHTS: A statistically significant and moderate positive correlation was verified between systolic blood pressure and plasma phosphate concentration in the whole sample (diabetic and non-diabetic), due to the diabetic chronic kidney disease group.A statistically significant and moderate positive correlation was verified between the diastolic blood pressure and plasma phosphate concentration in the whole sample (diabetic and non-diabetic), due to the diabetic chronic kidney disease group.A statistically significant and strong negative correlation was found between diastolic blood pressure and estimated glomerular filtration rate in the diabetic chronic kidney disease group, but there was no statistically significant correlation in the whole sample (diabetic and non-diabetic). ABSTRACT: Diabetic kidney disease features certain clinical and laboratorial characteristics that differ from chronic kidney disease of other etiologies. We performed a transversal study comparing some of these characteristics and assessed potential associations among blood pressure, plasma phosphate concentration and estimated glomerular filtration rate between patients with diabetic and non-diabetic chronic kidney disease.We found a positive correlation between both systolic and diastolic blood pressure and the plasma phosphate concentration in the diabetic kidney disease group, but not in the non-diabetic group. Also, diastolic blood pressure was negatively correlated with the estimated glomerular filtration rate in the diabetic group, yet not in the non-diabetic group.In conclusion, these data support the hypothesis of a close link between systolic and diastolic blood pressure and hyperphosphatemia, as well as between diastolic blood pressure and estimated glomerular filtration rate, in patients with diabetic kidney disease. Therapeutic approaches directed at these factors might prove to be important to delay the decline of renal function in the subgroup of patients with diabetic kidney disease. Copyright 2017 PBJ-Associação Porto Biomedical/Porto Biomedical Society.

Entities:  

Keywords:  Blood pressure; Diabetic kidney disease; Phosphatemia

Year:  2017        PMID: 32258786      PMCID: PMC6806749          DOI: 10.1016/j.pbj.2017.02.005

Source DB:  PubMed          Journal:  Porto Biomed J        ISSN: 2444-8664


  15 in total

1.  Dietary phosphate binding and loading alter kidney angiotensin-converting enzyme mRNA and protein content in 5/6 nephrectomized rats.

Authors:  Arttu Eräranta; Asko Riutta; Meng Fan; Jenni Koskela; Ilkka Tikkanen; Päivi Lakkisto; Onni Niemelä; Jyrki Parkkinen; Jukka Mustonen; Ilkka Pörsti
Journal:  Am J Nephrol       Date:  2012-04-19       Impact factor: 3.754

2.  Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure.

Authors:  S Spaia
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

Review 3.  Progression of diabetic nephropathy.

Authors:  Ryuichi Kikkawa; Daisuke Koya; Masakazu Haneda
Journal:  Am J Kidney Dis       Date:  2003-03       Impact factor: 8.860

4.  Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia.

Authors:  Shunsuke Yamada; Masanori Tokumoto; Narihito Tatsumoto; Masatomo Taniguchi; Hideko Noguchi; Toshiaki Nakano; Kosuke Masutani; Hiroaki Ooboshi; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  Am J Physiol Renal Physiol       Date:  2014-05-07

Review 5.  The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease.

Authors:  Hiroyuki Kobori; Masaomi Nangaku; L Gabriel Navar; Akira Nishiyama
Journal:  Pharmacol Rev       Date:  2007-09       Impact factor: 25.468

6.  Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences.

Authors:  Guillaume Jean; Eric Bresson; Jean-Claude Terrat; Thierry Vanel; Jean-Marc Hurot; Christie Lorriaux; Brice Mayor; Charles Chazot
Journal:  Nephrol Dial Transplant       Date:  2008-10-13       Impact factor: 5.992

7.  Arterial Stiffness and Chronic Kidney Disease.

Authors:  Anne-Sophie Garnier; Marie Briet
Journal:  Pulse (Basel)       Date:  2016-03-01

Review 8.  Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

Authors:  Sankar D Navaneethan; Suetonia C Palmer; Jonathan C Craig; Grahame J Elder; Giovanni F M Strippoli
Journal:  Am J Kidney Dis       Date:  2009-08-18       Impact factor: 8.860

Review 9.  Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease.

Authors:  Hiroyuki Kobori; Maki Urushihara
Journal:  Pflugers Arch       Date:  2012-08-24       Impact factor: 3.657

10.  Identifying parameters to distinguish non-diabetic renal diseases from diabetic nephropathy in patients with type 2 diabetes mellitus: a meta-analysis.

Authors:  Shuang Liang; Xue-Guang Zhang; Guang-Yan Cai; Han-Yu Zhu; Jian-Hui Zhou; Jie Wu; Pu Chen; Shu-Peng Lin; Qiang Qiu; Xiang-Mei Chen
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

View more
  2 in total

Review 1.  Phosphate Is a Cardiovascular Toxin.

Authors:  Maren Leifheit-Nestler; Isabel Vogt; Dieter Haffner; Beatrice Richter
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Hyperphosphatemia and its relationship with blood pressure, vasoconstriction, and endothelial cell dysfunction in hypertensive hemodialysis patients.

Authors:  Jinwoo Jung; Haekyung Jeon-Slaughter; Hang Nguyen; Jiten Patel; Kamalanathan K Sambandam; Shani Shastri; Peter Noel Van Buren
Journal:  BMC Nephrol       Date:  2022-08-23       Impact factor: 2.585

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.